文献速递艾滋病与性传播感染

在原发性HIV感染期间启动联合抗逆转录病毒治疗的患者中,多替拉韦单药治疗持续病毒抑制达192周(EARLY-SIMPLIFIED):一项随机、对照、多中心、非劣效性试验

Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial.
PubMed 文献 · Clin Infect Dis · 2023-01-01

EARLY-SIMPLIFIED是一项随机、开放标签、非劣效性试验,纳入在原发HIV-1感染后180天内启动cART且病毒载量抑制的101例HIV感染者,2:1随机分配至多替拉韦50mg每日一次单药治疗组(68例)或继续cART组(33例)。第96周符合方案人群中,多替拉韦单药组64/64(100%)vs cART组30/30(100%)显示病毒学应答,差异0.00%(95%CI上限6.22%),达到预设非劣效界值10%。第192周研究结束时,多替拉韦单药组(n=80)随访13308人周、cART组随访4897人周,两组均无病毒学失败。

要点

  • 原发HIV感染期间启动cART者,换用多替拉韦单药治疗第96周病毒学应答率100%,非劣效于继续cART。
  • 第192周研究结束时,多替拉韦单药组与cART组均无病毒学失败发生。
  • 第96周后解除随机化,患者可自行切换治疗组。

核心结论

  • 本试验提示,在原发HIV感染期间早期启动cART,换用多替拉韦单药治疗后可实现持续病毒学抑制。

研究设计与样本

  • EARLY-SIMPLIFIED为随机、开放标签、非劣效性试验,纳入在原发HIV-1感染记录后180天内启动cART且病毒载量抑制的HIV感染者101例,按2:1随机分配至多替拉韦50mg每日一次单药治疗组(68例)或继续cART组(33例)。
  • 主要终点为第48、96、144、192周病毒学失败的比例,非劣效界值为10%。
  • 第96周后解除随机化,允许患者按意愿切换治疗组。

主要发现

  • 第96周符合方案人群中,多替拉韦单药组64/64(100%)vs cART组30/30(100%)显示病毒学应答,差异0.00%(95%CI上限6.22%)。
  • 第192周研究结束时,多替拉韦单药组(n=80)随访13308人周、cART组随访4897人周,两组均无病毒学失败发生。

关键数值与推荐

  • 非劣效界值为10%。
  • 第96周多替拉韦单药组病毒学应答64/64(100%)vs cART组30/30(100%),差异0.00%(95%CI上限6.22%),达到预设非劣效水平。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Starting combination antiretroviral therapy (cART) during primary human immunodeficiency virus type 1 (HIV-1) infection results in a smaller HIV-1 latent reservoir, reduced immune activation, and less viral diversity compared to starting cART during chronic infection. We report results of a 4-year study designed to determine whether these properties would allow sustained virological suppression after simplification of cART to dolutegravir (DTG) monotherapy. METHODS: EARLY-SIMPLIFIED is a randomized, open-label, noninferiority trial. People with HIV (PWH) who started cART <180 days after a documented primary HIV-1 infection with suppressed viral load were randomized (2:1) to DTG monotherapy with 50 mg daily or continuation of cART. The primary endpoints were the proportion of PWH with viral failure at 48, 96, 144, and 192 weeks; noninferiority margin was 10%. After 96 weeks, randomization was lifted and patients were permitted to switch treatment groups as desired. RESULTS: Of 101 PWH randomized, 68 were assigned to DTG monotherapy and 33 to cART. At week 96 in the per-protocol population, 64/64 (100%) showed virological response in the DTG monotherapy group versus 30/30 (100%) in the cART group (difference, 0.00%; upper bound of 95% confidence interval 6.22%). This demonstrated noninferiority of DTG monotherapy at the prespecified level. At week 192, the study end, no virological failure occurred in either group during 13 308 and 4897 person weeks of follow-up for the DTG monotherapy (n = 80) and cART groups, respectively. CONCLUSIONS: This trial suggests that early cART initiation during primary HIV infection allows sustained virological suppression after switching to DTG monotherapy.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. West E, Zeeb M, Grube C, et al. Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial. Clin Infect Dis. 2023. PMID: 37338148. doi:10.1093/cid/ciad366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。